NPI 1992874077: Open Payments
NPI 1992874077. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$947 in 14 payments from 7 companies in 2025. Trend: 2023 $6,045 · 2024 $3,715 · 2025 $947
Food & beverage: $947
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 5 | $214 |
| Otsuka America Pharmaceutical, Inc. | 3 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $121 |
| ABBVIE INC. | 2 | $117 |
| Axsome Therapeutics, Inc. | 1 | $107 |
| Teva Pharmaceuticals USA, Inc. | 1 | $107 |
Products named: CAPLYTA, LYBALVI, REXULTI, QUVIVIQ, VRAYLAR, Auvelity, AUSTEDO XR, ARISTADA.
